YCT-529

DB21748InvestigationalSmall molecule

YCT-529 is under investigation in clinical trial NCT06542237 (Open Label, Repeat Dose Study Evaluating YCT-529 in Healthy Males).

Mechanism: Pharmacologically active on Retinoic acid receptor alpha
Curator reviewed
Formula / weight: C₂₉H₂₅NO₃ · 435.523 g/mol (avg)
Code names: YCT-529

Resolves to

Compound

Structure

InChIKeyQLXSCDXZOYRDAX-UHFFFAOYSA-NSMILESCC1=CC=C(C=C1)C1=CC(C)(C)OC2=C1C=C(C=C2)C1=CC=C(N1)C1=CC=C(C=C1)C(O)=O

Targets

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with YCT-529, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.